Aspirin Disrupts the Mtor-Raptor Complex and Potentiates the Anti-Cancer Activities of Sorafenib Via Mtorc1 Inhibition.

Danni Sun,Hongchun Liu,Xiaoyang Dai,Xingling Zheng,Juan Yan,Rongrui Wei,Xuhong Fu,Min Huang,Aijun Shen,Xun Huang,Jian Ding,Meiyu Geng

DOI: https://doi.org/10.1016/j.canlet.2017.06.029

IF: 9.756

2017-01-01

Cancer Letters

Abstract:Aspirin is associated with a reduced risk of cancer and delayed progression of malignant disease. Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)-mTOR signaling is believed to partially contribute to these anticancer effects, although the mechanism is unclear. In this study, we revealed the mechanism underlying the effects of aspirin on AMPK-mTOR signaling, and described a mechanism-based rationale for the use of aspirin in cancer therapy. We found that aspirin inhibited mTORC1 signaling through AMPK-dependent and -independent manners. Aspirin inhibited the AMPK-TSC pathway, thus resulting in the suppression of mTORC1 activity. In parallel, it directly disrupted the mTOR-raptor interaction. Additionally, the combination of aspirin and sorafenib showed synergetic effects via inhibiting mTORC1 signaling and the PI3K/AKT, MAPK/ERK pathways. Aspirin and sorafenib showed synergetic anticancer efficacy in the SMMC-7721 model. Our study provides mechanistic insights and a mechanism-based rationale for the roles of aspirin in cancer treatment.